The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.” ...
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
Shares of the Australian biotech rocketed up about 55% after the company announced results from a mid-stage study in generalized anxiety disorder.
The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.
The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes that can be used to make genetic medicines.
Analysts viewed results for one of Janux’s drug, a T cell engager aimed at metastatic prostate cancer, as potentially best-in-class in a field that’s crowded with competitors.
The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.